About our treatment
Methotrexate (MTX) is the disease modifying anti-rheumatic drug (DMARD) of first choice; patients responding inadequately to MTX, in Ireland, are eligible for anti-TNF agents, B-cell depleting therapy – rituximab (RTX), the antiIL-17 and anti-IL-6 receptor blocking drugs – or small molecule inhibitor – Tofacitinib. Biologics or targeted bio therapeutics have significantly improved outcomes of inflammatory arthritides. At 3 months, a significant response rate is well established for these agents. However, if introduced early, biologic DMARDs consistently produce better long-term outcome including joint damage, disability and employment. Therefore, identifying those patients most likely to respond and not develop toxicity would improve the cost-benefit.